Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 13,000 | |||
5 mg | 在庫あり | ¥ 33,000 | |||
10 mg | 在庫あり | ¥ 52,500 | |||
25 mg | 在庫あり | ¥ 106,500 | |||
50 mg | 在庫あり | ¥ 169,500 | |||
100 mg | 在庫あり | ¥ 226,500 | |||
500 mg | 在庫あり | ¥ 454,500 |
説明 | MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide. |
ターゲット&IC50 | PPARγ:18.25 μM |
In vivo | Diabetic db/db and MS-NASH mice are treated with MSDC-0602K by oral gavage, Liraglutide by s.c. injection, or combination MSDC-0602K + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis. Animal Model: Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice [1] Dosage: 30 mg/kg MSDC-0602K; 0.2 mg/kg Liraglutide Administration: MSDC-0602K gavage daily, Liraglutide s.c. every other day, or combined MSDC-0602K+ Liraglutide Result: MSDC-0602K corrected glycemia and reduced insulinemia when given alone, or in combination with Liraglutide. However, MSDC-0602K + Liraglutide combination more significantly improved glucose tolerance and liver histology[1]. |
別名 | MSDC-0602K, Azemiglitazone potassium |
分子量 | 409.5 |
分子式 | C19H16KNO5S |
CAS No. | 1314533-27-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (122.1 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MSDC-0602K 1314533-27-1 DNA Damage/DNA Repair Metabolism PPAR Azemiglitazone potassium Inhibitor inhibitor inhibit